Danaher Raises 2025 EPS Outlook, Names New CFO for 2026

Danaher Corp reported second-quarter 2025 sales of $5.94 billion, exceeding analyst expectations, with adjusted earnings per share of $1.80, beating estimates. The company saw strong biotechnology sales growth of 6% and diagnostic sales growth, though life sciences segment revenue remained flat. Danaher raised its full-year adjusted earnings guidance to $7.70-$7.80 per share, citing robust bioprocessing demand driven by pharmaceutical clients and a recovering China market. CEO Rainer Blair highlighted that monoclonal antibodies represent the largest investment area for customers, supporting long-term growth prospects. Despite challenges such as Chinese government policies affecting volume-based procurement and reimbursement, and soft demand in academic and government sectors, Danaher expects overall core revenue growth of around 3% for 2025. The company also announced a CFO transition, with Matthew Gugino set to succeed Matthew McGrew in early 2026.